All the latest worldwide HIV and AIDS news, including treatment, prevention, and hepatitis and TB co-infections. News from our own team of writers plus articles we have selected from other sources.

aidsmap hiv & aids news

RSS

← First12345...701Next →

hiv & aids news selected from other sources

  • Infectiousness and treatment as prevention
    Why are some HIV-positive men more infectious than others?
    HIV / AIDS News From Medical News Today | 8 hours ago

    A new study led by the Translational Genomics Research Institute (TGen) provides insights into the interplay among bacteria, viruses and the immune system during HIV infection.

  • Hepatitis C symptoms and diagnosis
    Hepatitis C annual report: progress made, but much more to do
    Public Health England | 28 July 2014

    New figures from PHE reveal hospital admissions, liver transplants and deaths from hepatitis C (HCV) have all risen in the UK.

  • Sex workers
    Decriminalise sex work to stop HIV, says Lord Fowler
    The Independent | 28 July 2014

    Speaking at the International Aids Conference in Melbourne, he said it was now widely accepted that fear of prosecution and discrimination was stopping people coming forward to be tested for HIV.

  • PrEP
    Does PrEP = a new gay sexual revolution?
    Bay Area Reporter | 26 July 2014

    Even though many health professionals portray PrEP as being "just another tool" to curtail the HIV epidemic, the charged rhetoric used by those for or against it – terms such as "party drug" or "Truvada whore" – suggests otherwise. As noted by a New York Times headline, PrEP raises the dramatic possibility of a new "sexual revolution" for gay men. While the idea frightens and even outrages many people, some advocates (including an increasingly vocal new generation of gay activists) are explicitly embracing the idea of less fear and more sexual choice, if not outright freedom.

  • Hepatitis C treatment
    In patients co-infected with HIV, combination antiretroviral therapy helps treat HCV
    HIV / AIDS News From Medical News Today | 25 July 2014

    Treatment of HIV patients co-infected with the hepatitis C virus (HCV) with an anti-retroviral drug therapy not only tackles HIV, but also reduces HCV replication, according to a new study lead by a University of Cincinnati researcher. The results were published in Science Translational Medicine.

  • Condoms and lubricant
    Young people speak out against stigma of youth condom use
    Key Correspondents | 25 July 2014

    Young people around the world are not receiving clear messages or support to use condoms to prevent HIV infection, according to delegates at the AIDS 2014 conference.

  • Starting treatment
    Men Who Have Sex With Men Getting Treatment Sooner
    MedPage Today | 25 July 2014

    Long-term trends indicate that European men who have sex with men are seeking treatment for HIV at earlier stages of their disease, researchers reported here.

  • Pharmaceutical industry
    Gilead's Sovaldi soars with sales of $3.48 billion
    Pharma Times | 25 July 2014

    An excellent day for Gilead Sciences has seen the US biotech post record-breaking sales of its hepatitis C pill Sovaldi and approval in the USA for Zydelig to treat three types of blood cancer.

  • Hepatitis C treatment
    Activists Hold Die-In to Protest High Price of Gilead’s Hepatitis C Drug
    Treatment Action Group | 25 July 2014

    Treatment activists at the 20th International AIDS Conference held a die-in to protest the exorbitant pricing of Sovaldi (sofosbuvir), Gilead’s new hepatitis C virus (HCV) drug. As Gregg Alton, Gilead’s executive vice president of corporate and medical affairs, spoke, activists brought him a liver on a silver platter while chanting “Pills Cost Pennies, Greed Costs Lives,” “Shame, Shame, Shame,” and “Pharma Greed Kills.” Their signs said, “Wanted: Crimes Against Access,” “Hep C Criminal,” and “Gilead Kills” as the O’Jay’s “For the Love of Money” blared in the background.

  • The Medicines Patent Pool (MPP) broadens collaboration with Gilead Sciences: Signs licence for Phase III medicine tenofovir alafenamide (TAF)
    Medicines Patent Pool | 25 July 2014

    The licence will allow manufacturers in India and China to develop generic versions of TAF for 112 countries that are home to more than 92% of people living with HIV in the developing world.

← First12345...922Next →

Hepatitis C news

WHO recommends global use of newest hepatitis C drugs, urges price reductions.

HIV update

Sign up for HIV update, our fortnightly news bulletin for people living with HIV in the UK.

Treatment as prevention

No-one with an undetectable viral load, gay or heterosexual, transmits HIV in two years of PARTNER study.

aidsmap news apps

Download the free aidsmap news iPhone and android apps.